Real-World study shows lutathera controls tumor growth in GEP-NET patients
NCT ID NCT04727723
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 22 times
Summary
This study followed 164 adults with advanced gut or pancreas neuroendocrine tumors (GEP-NETs) who were given Lutathera as part of their regular care. The goal was to see how long the treatment kept tumors from growing and how many patients saw their tumors shrink. Results help doctors understand the real-world benefits of this therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Alessandria, Italy
-
Novartis Investigative Site
Bologna, Italy
-
Novartis Investigative Site
Brescia, Italy
-
Novartis Investigative Site
Cona, Italy
-
Novartis Investigative Site
Florence, Italy
-
Novartis Investigative Site
Latina, Italy
-
Novartis Investigative Site
Meldola, Italy
-
Novartis Investigative Site
Messina, Italy
-
Novartis Investigative Site
Milan, Italy
-
Novartis Investigative Site
Naples, Italy
-
Novartis Investigative Site
Negrar, Italy
-
Novartis Investigative Site
Padova, Italy
-
Novartis Investigative Site
Pisa, Italy
-
Novartis Investigative Site
Reggio Emilia, Italy
-
Novartis Investigative Site
Rionero in Volture, Italy
-
Novartis Investigative Site
Roma, Italy
-
Novartis Investigative Site
Rozzano, Italy
-
Novartis Investigative Site
Torino, Italy
Conditions
Explore the condition pages connected to this study.